The frequency of factor V G1691A (Leiden) mutation in the healthy Kazakh population

Kaynakça (3)

1. Perry DJ, Pasi KJ. Resistence to activated protein C and Factor V leiden. QJM 1997;90:379-85. [CrossRef] Akar N. Factor V 1691 G-A mutation distribution in a healthy Turkish population. Turk J Hematol 2009;26:9-11.
2. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4. [CrossRef] Golden PB. An introduction to the history of the Turkic peoples: ethnogenesis and state- formation in Medieval and Early Modern Eurasia and the Middle East. Wiesbaden press. 1992.
3. Gokcumen O, Dulik MC, Pai AA, Zhadanov SI, Rubinstein S, Osipova LP Andreenkov OV, Tabikhanova LE, Gubina MA, Labuda D, Schurr TG. Genetic variation in the enig- matic Altaian Kazakhs of South-Central Russia: insights into Turkic population history. American J Physic Anthropol 2008;136:278-93. [CrossRef] Soucek S. A history of inner Asia. Cambridge: Cambridge University Press. 2000. 7. Lucotte G, Mercier G. Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis 2001;27:362-7. [CrossRef] 8. Gurgey A, Kudayarov DK, Tuncer M, Parlak H, Altay C. The factor V Leiden and prothrombin G20210A muta- tions in Kirghiz population. Thromb Haemost 2000;84:356. 9. Gurgey A, Rustemov R, Parlak H, Balta G. Prevalence of factor V Leiden and methylenetetrahydrofolate reduc- tase C677T mutations in Azerbaijan. Thromb Haemost 1998;80:520-1. 10. Rahimi Z, Nomani H, Mozafari H, Vaisi-Raygani A, Madani H, Malek-Khosravi S, Parsian A. Factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase polymorphism C677T are not associated with coronary artery disease and type 2 diabetes mellitus in western Iran. Blood coagulation and Fibrinolysis 2009;20:252-6. [CrossRef] 11. Lay MJ, Wittwer CT. Real-time fluorescence genotyping of factor V Leiden during rapid-cycle PCR. Clin Chem 1997;43:2262-5.